A recent Health Affairs study examines insurer spending and provider margins associated with Keytruda, highlighting significant differences among 340B-eligible hospitals, noneligible hospitals, and community-based physician practices. The findings offer important insight into how the site of cancer care can affect healthcare spending and provider revenue.
